Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients with History of Myocardial Infarction

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients with History of Myocardial Infarction

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders; Myocardial infarction; Stroke; Thrombosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PEGASUS; PEGASUS-TIMI 54
  • Sponsors AstraZeneca

    • Most Recent Events

    • 11 Nov 2022 Results of post-hoc exploratory analysis of patient selection for long-term secondary prevention with ticagrelor, published in the European Heart Journal
    • 15 Nov 2021 Results assessing Genetic Risk Score to Predict Peripheral Artery Disease from ENGAGE AF-TIMI 48, SOLID-TIMI 52, SAVOR-TIMI 53, PEGASUS-TIMI 54, and FOURIER trials presented at the American Heart Association Scientific Sessions 2021
    • 30 Mar 2020 Results (N= 40392), pooled analysis (data from PEGASUS-TIMI 54 and THEMIS trial) assessing addition of Ticagrelor to aspirin reduces major adverse limb events in stable patients with atherosclerosis, presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top